FTC Seeks Information on Amgen Deal
- Share via
Amgen Inc., which is acquiring rival Immunex Corp., said the two companies received a request for additional information from the Federal Trade Commission about their $16-billion combination.
The two drug makers “intend to respond promptly to the information request, which is a matter of routine and customary in these sorts of matters,” said Amgen spokesman Jeff Richardson. Amgen and Immunex said they still expect that the merger will be completed during the second half of 2002. It is the second request made by the FTC.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
